UVI 3003
UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.
Product Specifications
CAS Number
[847239-17-2]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; RAR/RXR
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/UVI_3003.html
Purity
99.57
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCCCCOC1=C(C2=CC(/C=C/C(O)=O)=CC=C2O)C=C3C(C(C)(CCC3(C)C)C)=C1
Molecular Formula
C28H36O4
Molecular Weight
436.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Zhu J, et al. The unexpected teratogenicity of RXR antagonist UVI3003 via activation of PPARγ in Xenopus tropicalis. Toxicol Appl Pharmacol. 2017 Jan 1;314:91-97.|[2]Hebert SL, et al. Effects of retinoic acid signaling on extraocular muscle myogenic precursor cells in vitro. Exp Cell Res. 2017 Dec 1;361 (1) :101-111.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6373395-01 0.1 mL
CDC14B (Dual Specificity Protein Phosphatase CDC14B, CDC14 Cell Division Cycle 14 Homolog B, Cdc14B1, Cdc14B2, CDC14B3, hCDC14B) (MaxLight 490)
Ask
View Details 
MBS6373395-02 5x 0.1 mL
CDC14B (Dual Specificity Protein Phosphatase CDC14B, CDC14 Cell Division Cycle 14 Homolog B, Cdc14B1, Cdc14B2, CDC14B3, hCDC14B) (MaxLight 490)
Ask
View Details 
MBS6204111-01 0.1 mL
WISP2 (WNT1-inducible-signaling Pathway Protein 2, WISP-2, CCN Family Member 5, CCN5, Connective Tissue Growth Factor-like Protein, CTGF-L, CTGFL, Connective Tissue Growth Factor-related Protein 58, CT58, UNQ228/PRO261) (MaxLight 490)
Ask
View Details